The Consortium of Food Allergy Research (CoFAR) has announced that it’s enrolled all of the test subjects needed for a double-blind, placebo-controlled clinical trial of a new peanut allergy treatment for children and adults.
The potential treatment, called Viaskin Peanut, is undergoing phase-two clinical trials in a multi-center, randomized study aimed at proving efficacy and gaining Food and Drug Administration approval.
Participants were vetted by allergen reactivity in a controlled food challenge. The study itself will be conducted in five locations with a total of 75 randomized participants aged 4-25 years. The study is expected to have two segments, the first evaluation of results happening in 12 months and the second after 30 months.
A ‘novel form of therapy for peanut allergy’
Dr. Hugh Sampson, Kurt Hirschhorn Professor of Pediatrics, Director of the Jaffe Food Allergy Institute and Dean of Translational Biomedical Science at The Mount Sinai Medical Center in New York, is the principal investigator of the CoFAR6 study. Sampson said:
We are very excited to have the opportunity to evaluate this novel form of therapy for peanut allergy and are undertaking a number of basic laboratory studies designed to help us better understand how this approach affects the immune system and allergic response.
CoFAR is funded by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health. This study is solely funded by the NIH.